69 related articles for article (PubMed ID: 23886028)
1. Glycemic control and the first use of oral antidiabetic agents among patients with type 2 diabetes mellitus.
Mitchell BD; Eby EL; Lage MJ
Curr Med Res Opin; 2013 Dec; 29(12):1587-97. PubMed ID: 23886028
[TBL] [Abstract][Full Text] [Related]
2. Glycemic control among patients with type 2 diabetes who initiate basal insulin: a retrospective cohort study.
Curtis B; Lage MJ
J Med Econ; 2014 Jan; 17(1):21-31. PubMed ID: 24195723
[TBL] [Abstract][Full Text] [Related]
3. Polypharmacy with oral antidiabetic agents: an indicator of poor glycemic control.
Willey CJ; Andrade SE; Cohen J; Fuller JC; Gurwitz JH
Am J Manag Care; 2006 Aug; 12(8):435-40. PubMed ID: 16886886
[TBL] [Abstract][Full Text] [Related]
4. Impact of depression on utilization patterns of oral hypoglycemic agents in patients newly diagnosed with type 2 diabetes mellitus: a retrospective cohort analysis.
Kalsekar ID; Madhavan SS; Amonkar MM; Douglas SM; Makela E; Elswick BL; Scott V
Clin Ther; 2006 Feb; 28(2):306-18. PubMed ID: 16678652
[TBL] [Abstract][Full Text] [Related]
5. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization.
Cooke CE; Lee HY; Tong YP; Haines ST
Curr Med Res Opin; 2010 Jan; 26(1):231-8. PubMed ID: 19921965
[TBL] [Abstract][Full Text] [Related]
6. A retrospective database analysis of neuropathic pain and oral antidiabetic medication use and adherence among Texas adults with type 2 diabetes enrolled in Medicaid.
Oladapo AO; Barner JC; Rascati KL; Strassels SA
Clin Ther; 2012 Mar; 34(3):605-13. PubMed ID: 22386828
[TBL] [Abstract][Full Text] [Related]
7. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
[TBL] [Abstract][Full Text] [Related]
8. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance.
Hertz RP; Unger AN; Lustik MB
Clin Ther; 2005 Jul; 27(7):1064-73. PubMed ID: 16154485
[TBL] [Abstract][Full Text] [Related]
9. Long-term maintenance of glucose control in veterans with type 2 diabetes mellitus using oral agents.
Swislocki AL; Meier JL; Najera SM; Noth RH
Metab Syndr Relat Disord; 2011 Dec; 9(6):469-73. PubMed ID: 21864034
[TBL] [Abstract][Full Text] [Related]
10. Effective switch from premixed to basal-prandial insulin to achieve glycemic goals in type 2 diabetes.
Lavernia F
Postgrad Med; 2010 May; 122(3):28-32. PubMed ID: 20463411
[TBL] [Abstract][Full Text] [Related]
11. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.
Bron M; Marynchenko M; Yang H; Yu AP; Wu EQ
Postgrad Med; 2012 Jan; 124(1):124-32. PubMed ID: 22314122
[TBL] [Abstract][Full Text] [Related]
12. Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.
Zhang Q; Rajagopalan S; Mavros P; Engel SS; Davies MJ; Yin D; Radican L
Curr Med Res Opin; 2010 Jul; 26(7):1697-703. PubMed ID: 20465367
[TBL] [Abstract][Full Text] [Related]
13. Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control.
Grimm M; Li Y; Brunell SC; Blase E
Postgrad Med; 2013 Sep; 125(5):101-8. PubMed ID: 24113668
[TBL] [Abstract][Full Text] [Related]
14. Real-world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapy.
Davis KL; Tangirala M; Meyers JL; Wei W
Curr Med Res Opin; 2013 Sep; 29(9):1083-91. PubMed ID: 23734906
[TBL] [Abstract][Full Text] [Related]
15. Important treatment gaps in vascular protection for the elderly after type 2 diabetes therapy initiation.
Guénette L; Breton MC; Hamdi H; Grégoire JP; Moisan J
Can J Cardiol; 2013 Dec; 29(12):1593-8. PubMed ID: 24183301
[TBL] [Abstract][Full Text] [Related]
16. Difficulty adhering to antidiabetic treatment: factors associated with persistence and compliance.
Guénette L; Moisan J; Breton MC; Sirois C; Grégoire JP
Diabetes Metab; 2013 May; 39(3):250-7. PubMed ID: 23523643
[TBL] [Abstract][Full Text] [Related]
17. Clinical and economic outcomes associated with National Kidney Foundation guideline-concordant oral antidiabetic drug treatment among type 2 diabetes patients with chronic kidney disease.
Chen SY; Siu K; Kovacs B; Stokes M; Rao P; Sander S; Boulanger L
Curr Med Res Opin; 2012 Apr; 28(4):493-501. PubMed ID: 22364567
[TBL] [Abstract][Full Text] [Related]
18. Initial and subsequent therapy for newly diagnosed type 2 diabetes patients treated in primary care using data from a vendor-based electronic health record.
Brouwer ES; West SL; Kluckman M; Wallace D; Masica AL; Ewen E; Kudyakov R; Cheng D; Bowen J; Fleming NS
Pharmacoepidemiol Drug Saf; 2012 Sep; 21(9):920-8. PubMed ID: 22250059
[TBL] [Abstract][Full Text] [Related]
19. Treatment intensification using long-acting insulin -predictors of future basal insulin supported oral therapy in the DIVE registry.
Danne T; Bluhmki T; Seufert J; Kaltheuner M; Rathmann W; Beyersmann J; Bramlage P;
BMC Endocr Disord; 2015 Oct; 15():54. PubMed ID: 26446863
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus.
Yki-Järvinen H
Diabetes Metab Res Rev; 2002; 18 Suppl 3():S77-81. PubMed ID: 12324990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
